Potential Chemopreventive Role of Proton Pump Inhibitors in Head and Neck Cancer: Insights from a Nested Case-Control Analysis of a National Health Screening Cohort

: This study investigated the potential chemopreventive role of proton pump inhibitor (PPI) use in relation to the occurrence of head and neck cancer (HNC) within a national cohort amid concerns of PPI overprescription. : From a cohort of 1,137,861 individuals and 219,673,817 medical claim records c...

Full description

Saved in:
Bibliographic Details
Published in:Journal of personalized medicine 2024-12, Vol.15 (1), p.8
Main Authors: Lee, Joong Seob, Jo, Soomin, Kang, Ho Suk, Kwon, Mi Jung, Wee, Jee Hye, Kang, Jeong Wook, Choi, Hyo Geun, Kim, Heejin
Format: Article
Language:English
Subjects:
Cohort analysis
Colorectal cancer
Comorbidity
Esophagus
Ethics
Exocrine glands
Head & neck cancer
Head and neck
Laryngeal cancer
Larynx
Proton pump inhibitors
Regression analysis
Side effects
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:: This study investigated the potential chemopreventive role of proton pump inhibitor (PPI) use in relation to the occurrence of head and neck cancer (HNC) within a national cohort amid concerns of PPI overprescription. : From a cohort of 1,137,861 individuals and 219,673,817 medical claim records collected between 2005 and 2019, 1677 HNC patients were identified and matched 1:4 with 6708 controls after adjusting for covariates. Odds ratios (ORs) for PPI use and its duration in relation to HNC and its subsites were estimated using propensity score overlap-weighted multivariable logistic regression. Additional subgroup analyses were performed based on age, sex, income level, and geographic region. : In the crude model, both current (OR 7.85 [95% CI 6.52-9.44]) and past PPI (OR 1.44 [95% CI 1.23-1.70]) use were associated with increased odds for HNC. However, after overlap weighting, this association reversed for both current (aOR 0.14 [95% CI 0.11-0.17]) and past PPI (aOR 0.69 [95% CI 0.60-0.79]). Subsite analysis showed reduced odds for hypopharyngeal (aOR 0.33, [95% CI 0.25-0.43]) and laryngeal cancer (aOR 0.19 [95% CI 0.16-0.22]) in current PPI users and similar results for past users. : This study suggests a potential chemopreventive effect of PPIs, particularly in hypopharyngeal and laryngeal cancers. Additional studies are required to investigate the mechanisms underlying the association of the development of HNC with PPI use.
ISSN:2075-4426
2075-4426
DOI:10.3390/jpm15010008